Let’s be honest and acknowledge that the censure of Rep. Laurel Libby by the Legislature, and the negative response from many citizens, has nothing to do with limiting her freedom of speech.

February 28, 2025 EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug The European Union's medicines regulator on Friday reiterated its positive recommendation for ...

How many Broadway shows has Libby Lloyd been in? Libby Lloyd has appeared on Broadway in 3 shows. How many West End shows has Libby Lloyd been in? Libby Lloyd has not appeared in the West End.

Maine State Rep. Laurel Libby has filed a lawsuit against Speaker of the House Ryan Fecteau after she was censured on Feb. 15 for her social media post about a trans high school athlete.

“When Libby (Fandel) misses a first throw, it’s always the first one,” Lilly said. “Then she always makes the second.” At the 3:17 mark of the first quarter, Fandel missed the ...

Liberal leader Libby Mettam also faced reporters on Sunday, and left wide open the prospect she would step down from the role. Premier Roger Cook has declared he has a clear mandate to put in ...

The prospect of an expensive court fight with the Trump administration irked Ms Libby. “Governor Mills was very serious about that. I think it’s the wrong call.

Premier Roger Cook and Liberal leader Libby Mettam. Loading Premier Roger Cook has consistently said he expects to lose seats this election and Labor insiders say they are bracing for a loss of 12 ...

TOKYO -- Japanese drugmaker Eisai's share price is hovering around a 10-year low of 4,300 yen, weighed down by poor U.S. sales of its much-touted Alzheimer's treatment Leqembi and the company's ...

The U.K.’s National Institute for Health and Care Excellence on Thursday again denied to recommend Biogen and Eisai’s Alzheimer’s disease therapy Leqembi, noting that its clinical benefits do not ...

In August, NICE declined to recommend Biogen and Eisai’s Leqembi (lecanemab) for reimbursement. Three months later, NICE followed with the same decision on Lilly’s Kisunla (donanemab).